Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NYSE:ANVS NASDAQ:ENTA NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.22+13.0%$0.70$0.40▼$2.36$65.33M1.111.64 million shs827,774 shsANVSAnnovis Bio$2.29+0.5%$2.57$1.11▼$10.54$44.62M1.65222,705 shs169,313 shsENTAEnanta Pharmaceuticals$8.85-0.4%$7.77$4.09▼$13.37$189.20M0.84159,307 shs103,778 shsTVGNTevogen Bio$0.87-1.5%$1.05$0.26▼$3.09$170.43M-0.78636,483 shs543,280 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%+4.27%+73.10%+110.71%-40.78%ANVSAnnovis Bio0.00%-1.25%-11.54%-28.36%-72.82%ENTAEnanta Pharmaceuticals0.00%+5.36%+26.61%+18.47%-27.10%TVGNTevogen Bio0.00%-4.79%-0.31%-39.41%+82.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.22+13.0%$0.70$0.40▼$2.36$65.33M1.111.64 million shs827,774 shsANVSAnnovis Bio$2.29+0.5%$2.57$1.11▼$10.54$44.62M1.65222,705 shs169,313 shsENTAEnanta Pharmaceuticals$8.85-0.4%$7.77$4.09▼$13.37$189.20M0.84159,307 shs103,778 shsTVGNTevogen Bio$0.87-1.5%$1.05$0.26▼$3.09$170.43M-0.78636,483 shs543,280 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%+4.27%+73.10%+110.71%-40.78%ANVSAnnovis Bio0.00%-1.25%-11.54%-28.36%-72.82%ENTAEnanta Pharmaceuticals0.00%+5.36%+26.61%+18.47%-27.10%TVGNTevogen Bio0.00%-4.79%-0.31%-39.41%+82.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.83Moderate Buy$3.30170.49% UpsideANVSAnnovis Bio 2.60Moderate Buy$17.33656.58% UpsideENTAEnanta Pharmaceuticals 3.00Buy$22.25151.41% UpsideTVGNTevogen Bio 3.00Buy$10.001,054.20% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ALXO, ENTA, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/3/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.009/2/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/12/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$24.00 ➝ $25.008/8/2025ANVSAnnovis BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/28/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.006/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/10/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $12.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/AANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AENTAEnanta Pharmaceuticals$67.64M2.80N/AN/A$6.08 per share1.46TVGNTevogen BioN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%11/24/2025 (Estimated)TVGNTevogen Bio-$13.73MN/A0.00∞N/AN/AN/A-775.49%11/10/2025 (Estimated)Latest ANVS, ALXO, ENTA, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025N/ATVGNTevogen Bio-$0.05-$0.03+$0.02-$0.03N/AN/A8/12/2025Q2 2025ALXOALX Oncology-$0.46-$0.49-$0.03-$0.49N/AN/A8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.114.524.52ANVSAnnovis BioN/A7.657.65ENTAEnanta PharmaceuticalsN/A5.005.00TVGNTevogen BioN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%ANVSAnnovis Bio15.83%ENTAEnanta Pharmaceuticals94.99%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%ANVSAnnovis Bio20.80%ENTAEnanta Pharmaceuticals13.89%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.55 million42.31 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableTVGNTevogen Bio3196.71 million52.64 millionN/AANVS, ALXO, ENTA, and TVGN HeadlinesRecent News About These CompaniesTevogen Bio's (TVGN) "Buy" Rating Reiterated at D. Boral Capital2 hours ago | americanbankingnews.comTevogen Bio's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 6 at 8:54 AM | marketbeat.comTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on ...September 4 at 6:02 PM | bakersfield.comBTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and LymphomasSeptember 4 at 3:48 PM | globenewswire.comTevogen Bio Highlights Promising Clinical Results for TVGN 489 in Treating SARS-CoV-2 in Immunocompromised PatientsSeptember 3, 2025 | quiverquant.comQTevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2September 3, 2025 | globenewswire.comTevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 28, 2025 | finanznachrichten.deTevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term ValueAugust 27, 2025 | quiverquant.comQTevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 27, 2025 | globenewswire.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health EquityAugust 26, 2025 | markets.businessinsider.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health EquityAugust 26, 2025 | globenewswire.comTevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025August 25, 2025 | quiverquant.comQTevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsAugust 25, 2025 | globenewswire.comTevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | markets.businessinsider.comTevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and InnovationAugust 22, 2025 | quiverquant.comQTevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Announces Earnings ResultsAugust 21, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)August 20, 2025 | marketbeat.comTevogen finalizes agreement for up to $50M in financingAugust 19, 2025 | msn.comREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...August 19, 2025 | bakersfield.comBREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development EffortsAugust 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025If Qualcomm Holds $145, Its Next Move Could Be MassiveBy Sam Quirke | August 12, 20253 Reasons Salesforce Is a Bargain Right NowBy Sam Quirke | August 22, 20253 Cheap Stocks That Shouldn't Be This LowBy Gabriel Osorio-Mazilli | August 25, 2025ANVS, ALXO, ENTA, and TVGN Company DescriptionsALX Oncology NASDAQ:ALXO$1.22 +0.14 (+12.96%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.16 -0.05 (-4.51%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Annovis Bio NYSE:ANVS$2.29 +0.01 (+0.48%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$2.30 +0.00 (+0.17%) As of 09/5/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Enanta Pharmaceuticals NASDAQ:ENTA$8.85 -0.04 (-0.45%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$9.00 +0.15 (+1.68%) As of 09/5/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Tevogen Bio NASDAQ:TVGN$0.87 -0.01 (-1.47%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.39%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
